The Analyst Verdict: Charles River In The Eyes Of 10 Experts
Portfolio Pulse from Benzinga Insights
Charles River Laboratories (NYSE:CRL) has been analyzed by 10 analysts, showing a range of opinions from bullish to bearish. Recent analyst actions have predominantly lowered price targets, with the average target now at $218.3, down 13.6% from a previous $252.67. Despite revenue challenges, Charles River shows strong financial health with high net margins, ROE, and ROA, and a conservative debt approach.
September 20, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Charles River Laboratories has received mixed analyst ratings, with a trend of lowered price targets. The average target is now $218.3, a 13.6% decrease from the previous average. Despite revenue challenges, the company maintains strong financial health indicators.
The majority of analysts have lowered their price targets for CRL, indicating a bearish sentiment. The average price target has decreased significantly, suggesting potential short-term downward pressure on the stock. However, the company's strong financial health metrics may mitigate some negative impacts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100